Close Menu
Home » ACOG Issues Favorable Opinion for Non-invasive Prenatal Test Makers

ACOG Issues Favorable Opinion for Non-invasive Prenatal Test Makers

Nov 21, 2012
|
staff reporter

NEW YORK (GenomeWeb News) – The American College of Obstetricians and Gynecologists has issued an opinion that non-invasive prenatal testing using cell-free fetal DNA can be offered to patients at increased risk of aneuploidy — a decision that is favorable to firms such as Sequenom, Ariosa Diagnostics, and Verinata Health.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Gene Editing for the Gold

Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.

Variant Linked to Heart Failure Risk

A genetic alteration appears to increase heart failure risk among people of African descent, according to the Washington Post.

A Different Future

In his look back at the past decade, BuzzFeed News' Peter Aldhous writes that direct-to-consumer genetic testing has led to "Facebook for genes."

Nature Examines Lifespans, Fast and Accurate Method for Long-Read Assembly, More

In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

What's Popular?

In Clinical Sequencing

  1. At ASH, Researchers Discuss Rapid AML Nanopore Sequencing Assay for Analyzing Actionable Alterations

  2. Online Tool to Select Secondary Findings May Shorten Genetic Counseling Sessions

  3. Gene Panel Finds Pathogenic Variants Missed by Standard Tests in 5 Percent of Familial Cancer Cases

  4. Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials

  5. ASH Study: Germline Testing Identifies Cancer Risk Mutations, VUS in Older AML Patients

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.